This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacobs, A. H. Articles by Heiss, W.-D. Search for Related Content PubMed PubMed Citation Articles by Jacobs, A. H. Articles by Heiss, W.-D.

Imaging-Guided Gene Therapy of Experimental Gliomas

Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research, Center for Molecular Medicine, and Department of Neurology, University of Cologne, Cologne, Germany

Requests for reprints: Andreas H. Jacobs, Laboratory for Gene Therapy and Molecular Imaging, Department of Neurology, University of Cologne, Max Planck Institute for Neurological Research, Gleuelerstraße 50, 50931 Cologne, Germany. Phone: 49-221-4726-310; Fax: 49-221-4726-298; E-mail: Andreas.Jacobs{at}nf.mpg.de.

To further develop gene therapy for patients with glioblastomas, an experimental gene therapy protocol was established comprising a series of imaging parameters for (i) noninvasive assessment of viable target tissue followed by (ii) targeted application of herpes simplex virus type 1 (HSV-1) amplicon vectors and (iii) quantification of treatment effects by imaging. We show that viable target tissue amenable for application of gene therapy vectors can be identified by multitracer positron emission tomography (PET) using 2-¹⁸F-fluoro-2-deoxy-D-glucose, methyl-¹¹C-L-methionine, or 3'-deoxy-3'-¹⁸F-fluoro-L-thymidine ([¹⁸F]FLT). Targeted application of HSV-1 amplicon vectors containing two therapeutic genes with synergistic antitumor activity (Escherichia coli cytosine deaminase, cd, and mutated HSV-1 thymidine kinase, tk39, fused to green fluorescent protein gene, gfp) leads to an overall response rate of 68%, with 18% complete responses and 50% partial responses. Most importantly, we show that the "tissue dose" of HSV-1 amplicon vector–mediated gene expression can be noninvasively assessed by 9-[4-¹⁸F-fluoro-3-(hydroxymethyl)butyl]guanine ([¹⁸F]FHBG) PET. Therapeutic effects could be monitored by PET with significant differences in [¹⁸F]FLT accumulation in all positive control tumors and 72% in vivo transduced tumors (P = 0.01) as early as 4 days after prodrug therapy. For all stably and in vivo transduced tumors, cdIREStk39gfp gene expression as measured by [¹⁸F]FHBG-PET correlated with therapeutic efficiency as measured by [¹⁸F]FLT-PET. These data indicate that imaging-guided vector application with determination of tissue dose of vector-mediated gene expression and correlation to induced therapeutic effect using multimodal imaging is feasible. This strategy will help in the development of safe and efficient gene therapy protocols for clinical application. [Cancer Res 2007;67(4):1706–15]

This article has been cited by other articles:

				H. Miletic, Y. H. Fischer, T. Giroglou, M. A. Rueger, A. Winkeler, H. Li, U. Himmelreich, W. Stenzel, A. H. Jacobs, and D. von Laer Normal Brain Cells Contribute to the Bystander Effect in Suicide Gene Therapy of Malignant Glioma Clin. Cancer Res., November 15, 2007; 13(22): 6761 - 6768. [Abstract] [Full Text] [PDF]

				H.-J. Wester Nuclear Imaging Probes: from Bench to Bedside Clin. Cancer Res., June 15, 2007; 13(12): 3470 - 3481. [Abstract] [Full Text] [PDF]